Coya Therapeutics (NASDAQ:COYA) Earns “Buy” Rating from Chardan Capital

Coya Therapeutics (NASDAQ:COYA)‘s stock had its “buy” rating reaffirmed by research analysts at Chardan Capital in a research report issued on Thursday,Benzinga reports. They currently have a $14.00 target price on the stock. Chardan Capital’s target price points to a potential upside of 100.00% from the stock’s previous close.

Several other analysts have also weighed in on the stock. D. Boral Capital reiterated a “buy” rating and set a $15.00 target price on shares of Coya Therapeutics in a research note on Thursday. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price objective on shares of Coya Therapeutics in a research report on Monday, November 11th.

Coya Therapeutics Stock Performance

Shares of COYA stock traded up $0.47 during mid-day trading on Thursday, reaching $7.00. 400,429 shares of the company were exchanged, compared to its average volume of 67,476. The business’s 50 day simple moving average is $5.86 and its 200 day simple moving average is $6.40. The company has a market capitalization of $116.97 million, a P/E ratio of -10.77 and a beta of 0.47. Coya Therapeutics has a fifty-two week low of $4.75 and a fifty-two week high of $10.69.

Coya Therapeutics (NASDAQ:COYA) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.15. On average, analysts forecast that Coya Therapeutics will post -1.15 EPS for the current year.

Insider Buying and Selling at Coya Therapeutics

In other Coya Therapeutics news, CEO Arun Swaminathan acquired 5,000 shares of Coya Therapeutics stock in a transaction dated Monday, November 11th. The stock was acquired at an average cost of $7.34 per share, for a total transaction of $36,700.00. Following the completion of the transaction, the chief executive officer now owns 5,000 shares in the company, valued at approximately $36,700. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Over the last three months, insiders have purchased 9,510 shares of company stock worth $69,615. 9.80% of the stock is owned by insiders.

Institutional Trading of Coya Therapeutics

Several hedge funds have recently added to or reduced their stakes in COYA. Geode Capital Management LLC raised its stake in shares of Coya Therapeutics by 3.3% in the 3rd quarter. Geode Capital Management LLC now owns 142,309 shares of the company’s stock worth $918,000 after buying an additional 4,485 shares in the last quarter. Renaissance Technologies LLC acquired a new position in Coya Therapeutics during the second quarter worth about $101,000. GHP Investment Advisors Inc. bought a new stake in Coya Therapeutics in the third quarter worth about $169,000. Finally, Newbridge Financial Services Group Inc. acquired a new stake in Coya Therapeutics in the 4th quarter valued at about $401,000. Institutional investors own 39.75% of the company’s stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.